ArticleLeukemiaPublished
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Mercer County
Publication record
- Type
- Article
- Venue
- Leukemia
- Published
- Topic
- Clinical care
- PubMed ID
- 42827117
- Open access
- Yes, open
- Added to directory
- Source checked